Clinical trial
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in…
NCT00293267 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00293267 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2) |
| Official title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | raltegravir potassium, Comparator: Placebo |
| Enrollment | 352 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | May 1, 2011 |
| First posted | Feb 17, 2006 |
| Last update posted | Sep 7, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: